doi:10.48130/pedi-0026-0006

[1]

Ogle GD, Wang F, Haynes A, Gregory GA, King TW, et al. 2025. Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0. Diabetes Research and Clinical Practice 225:112277

doi: 10.1016/j.diabres.2025.112277

[2]

Duncan BB, Magliano DJ, Boyko EJ. 2025. IDF Diabetes Atlas 11th edition 2025: global prevalence and projections for 2050. Nephrology Dialysis Transplantation 41(1):7−9

doi: 10.1093/ndt/gfaf177

[3]

Li Y, Qian K, Wu D, Wang X, Cui H, et al. 2023. Incidence of childhood Type 1 diabetes in Beijing during 2011−2020 and predicted incidence for 2025−2035: a multicenter, hospitalization-based study. Diabetes Therapy 14:519−529

doi: 10.1007/s13300-023-01367-8

[4]

Roche EF, McKenna AM, O'Regan M, Ryder KJ, Fitzgerald HM, et al. 2023. The incidence of type 1 diabetes in children under 15 years of age is rising again—a nationwide study. European Journal of Pediatrics 182:4615−4623

doi: 10.1007/s00431-023-05125-7

[5]

Sundberg F, Barnard K, Cato A, de Beaufort C, DiMeglio LA, et al. 2017. Managing diabetes in preschool children. Pediatric Diabetes 18:499−517

doi: 10.1111/pedi.12554

[6]

American Diabetes Association Professional Practice Committee. 2025. Children and adolescents: standards of care in diabetes—2025. Diabetes Care 48:S283−S305

doi: 10.2337/dc25-S014

[7]

Kariyawasam D, Morin C, Casteels K, Le Tallec C, Sfez A, et al. 2022. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial. The Lancet Digital Health 4:e158−e168

doi: 10.1016/S2589-7500(21)00271-5

[8]

Dovc K, Van Name M, Jenko Bizjan B, Rusak E, Piona C, et al. 2022. Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (VibRate): a multinational prospective observational real-world cohort study. Diabetes, Obesity and Metabolism 24:564−569

doi: 10.1111/dom.14607

[9]

Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, et al. 2019. State of type 1 diabetes management and outcomes from the T1D exchange in 2016−2018. Diabetes Technology & Therapeutics 21:66−72

doi: 10.1089/dia.2018.0384

[10]

Sundberg F, Forsander G. 2014. Detection and treatment efficacy of hypoglycemic events in the everyday life of children younger than 7 yr. Pediatric Diabetes 15:34−40

doi: 10.1111/pedi.12057

[11]

Van Name MA, Hilliard ME, Boyle CT, Miller KM, DeSalvo DJ, et al. 2018. Nighttime is the worst time: parental fear of hypoglycemia in young children with type 1 diabetes. Pediatric Diabetes 19:114−120

doi: 10.1111/pedi.12525

[12]

Tsoukas MA, Majdpour D, Yale JF, El Fathi A, Garfield N, et al. 2021. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial. The Lancet Digital Health 3:e723−e732

doi: 10.1016/S2589-7500(21)00139-4

[13]

Tauschmann M, Allen JM, Wilinska ME, Thabit H, Acerini CL, et al. 2016. Home use of day-and-night hybrid closed-loop insulin delivery in suboptimally controlled adolescents with type 1 diabetes: a 3-week, free-living, randomized crossover trial. Diabetes Care 39:2019−2025

doi: 10.2337/dc16-1094

[14]

Fuchs J, Hovorka R. 2021. Benefits and challenges of current closed-loop technologies in children and young people with type 1 diabetes. Frontiers in Pediatrics 9:679484

doi: 10.3389/fped.2021.679484

[15]

Henry Z, Villar Fimbel S, Bendelac N, Perge K, Thivolet C. 2024. Beneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristics. Diabetes, Obesity and Metabolism 26:557−566

doi: 10.1111/dom.15344

[16]

Mameli C, Smylie GM, Galati A, Rapone B, Cardona-Hernandez R, et al. 2023. Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review. European Journal of Pediatrics 182:1949−1963

doi: 10.1007/s00431-023-04833-4

[17]

Buckingham BA, Forlenza GP, Pinsker JE, Christiansen MP, Wadwa RP, et al. 2018. Safety and feasibility of the OmniPod hybrid closed-loop system in adult, adolescent, and pediatric patients with type 1 diabetes using a personalized model predictive control algorithm. Diabetes Technology & Therapeutics 20:257−262

doi: 10.1089/dia.2017.0346

[18]

Beck RW, Kanapka LG, Breton MD, Brown SA, Wadwa RP, et al. 2023. A meta-analysis of randomized trial outcomes for the t: slim X2 insulin pump with control-IQ technology in youth and adults from age 2 to 72. Diabetes Technology & Therapeutics 25:329−342

doi: 10.1089/dia.2022.0558

[19]

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, et al. 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71

doi: 10.1136/bmj.n71

[20]

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, et al. 2008. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924−926

doi: 10.1136/bmj.39489.470347.AD

[21]

The Cochrane Collaboration. 2020. Review Manager (RevMan) [Computer program]. Version 5.4. Copenhagen: The Cochrane Collaboration

[22]

Battelino T, Kuusela S, Shetty A, Rabbone I, Cherubini V, et al. 2025. Efficacy and safety of automated insulin delivery in children aged 2−6 years (LENNY): an open-label, multicentre, randomised, crossover trial. The Lancet Diabetes & Endocrinology 13:662−673

doi: 10.1016/S2213-8587(25)00091-9

[23]

Wadwa RP, Reed ZW, Buckingham BA, DeBoer MD, Ekhlaspour L, et al. 2023. Trial of hybrid closed-loop control in young children with type 1 diabetes. New England Journal of Medicine 388:991−1001

doi: 10.1056/NEJMoa2210834

[24]

Ware J, Allen JM, Boughton CK, Wilinska ME, Hartnell S, et al. 2022. Randomized trial of closed-loop control in very young children with type 1 diabetes. New England Journal of Medicine 386:209−219

doi: 10.1056/NEJMoa2111673

[25]

Biester T, Berget C, Boughton C, Cudizio L, Ekhlaspour L, et al. 2024. International society for pediatric and adolescent diabetes clinical practice consensus guidelines 2024: diabetes technologies - insulin delivery. Hormone Research in Paediatrics 97:636−662

doi: 10.1159/000543034

[26]

Dovc K, Boughton C, Tauschmann M, Thabit H, Bally L, et al. 2019. Young children have higher variability of insulin requirements: observations during hybrid closed-loop insulin delivery. Diabetes Care 42:1344−1347

doi: 10.2337/dc18-2625

[27]

Reiss AL, Jo B, Arbelaez AM, Tsalikian E, Buckingham B, et al. 2022. A Pilot randomized trial to examine effects of a hybrid closed-loop insulin delivery system on neurodevelopmental and cognitive outcomes in adolescents with type 1 diabetes. Nature Communications 13:4940

doi: 10.1038/s41467-022-32289-x

[28]

de Bock M, Agwu JC, Deabreu M, Dovc K, Maahs DM, et al. 2024. International society for pediatric and adolescent diabetes clinical practice consensus guidelines 2024: glycemic targets. Hormone Research in Paediatrics 97:546−554

doi: 10.1159/000543266

[29]

Tysoe O. 2022. Cognitive function in T1DM improved by hybrid closed-loop insulin delivery. Nature Reviews Endocrinology 18:657

doi: 10.1038/s41574-022-00752-w

[30]

Gaudieri PA, Chen R, Greer TF, Holmes CS. 2008. Cognitive function in children with type 1 diabetes: a meta-analysis. Diabetes Care 31:1892−1897

doi: 10.2337/dc07-2132

[31]

Beck RW, Bergenstal RM, Cheng P, Kollman C, Carlson AL, et al. 2019. The relationships between time in range, hyperglycemia metrics, and HbA1c. Journal of Diabetes Science and Technology 13:614−626

doi: 10.1177/1932296818822496

[32]

Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, et al. 2019. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 42:1593−1603

doi: 10.2337/dci19-0028

[33]

Bekiari E, Kitsios K, Thabit H, Tauschmann M, Athanasiadou E, et al. 2018. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ 361:k1310

doi: 10.1136/bmj.k1310

[34]

Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. 2017. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. The Lancet Diabetes & Endocrinology 5:501−512

doi: 10.1016/S2213-8587(17)30167-5

[35]

Yang Q, Zeng B, Hao J, Yang Q, Sun F. 2024. Real-world glycaemic outcomes of automated insulin delivery in type 1 diabetes: a meta-analysis. Diabetes, Obesity & Metabolism 26:3753−3763

doi: 10.1111/dom.15718

[36]

Ferreira ROM, Trevisan T, Pasqualotto E, Schmidt P, Chavez MP, et al. 2024. Efficacy of the hybrid closed-loop insulin delivery system in children and adolescents with type 1 diabetes: a meta-analysis with trial sequential analysis. Archives of Endocrinology and Metabolism 68:e230280

doi: 10.20945/2359-4292-2023-0280

[37]

Salehi P, Roberts AJ, Kim GJ. 2019. Efficacy and safety of real-life usage of MiniMed 670G automode in children with type 1 diabetes less than 7 years old. Diabetes Technology & Therapeutics 21:448−451

doi: 10.1089/dia.2019.0123

[38]

Sherr JL, Bode BW, Forlenza GP, Laffel LM, Schoelwer MJ, et al. 2022. Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: a single-arm multicenter clinical trial. Diabetes Care 45:1907−1910

doi: 10.2337/dc21-2359

[39]

Forlenza GP, Ekhlaspour L, DiMeglio LA, Fox LA, Rodriguez H, et al. 2022. Glycemic outcomes of children 2–6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial. Pediatric Diabetes 23:324−329

doi: 10.1111/pedi.13312

[40]

Uslu NG, Kizilay DO, Demir G, Altinok YA, Darcan S, et al. 2025. Is automated insulin delivery system therapy safe and effective in children under seven years old? Journal of Clinical Research in Pediatric Endocrinology 17:153−160

doi: 10.4274/jcrpe.galenos.2024.2024-11-2

[41]

Pulkkinen MA, Varimo TJ, Hakonen ET, Harsunen MH, Hyvönen ME, et al. 2023. MiniMed 780G™ in 2-to 6-year-old children: safety and clinical outcomes after the first 12 weeks. Diabetes Technology & Therapeutics 25:100−107

doi: 10.1089/dia.2022.0313

[42]

Tauschmann M, Allen JM, Nagl K, Fritsch M, Yong J, et al. 2019. Home use of day-and-night hybrid closed-loop insulin delivery in very young children: a multicenter, 3-week, randomized trial. Diabetes Care 42:594−600

doi: 10.2337/dc18-1881

[43]

Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, et al. 2022. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. The Lancet Digital Health 4:e245−e255

doi: 10.1016/S2589-7500(22)00020-6

[44]

Ware J, Bergford S, Calhoun P, Sibayan J, Wilinska ME, et al. 2026. Real-world clinical impact of using personal glucose targets in a hybrid closed-loop system differs according to age. Diabetes Technology & Therapeutics 28:167−174

doi: 10.1177/15209156251376010

[45]

Fan W, Deng C, Xu R, Liu Z, Leslie RD, et al. 2025. Efficacy and safety of automated insulin delivery systems in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetes & Metabolism Journal 49:235−251

doi: 10.4093/dmj.2024.0130

[46]

Alwan H, Wilinska ME, Ruan Y, Da Silva J, Hovorka R. 2025. Real-world evidence analysis of a hybrid closed-loop system. Journal of Diabetes Science and Technology 19:385−389

doi: 10.1177/19322968231185348

[47]

Karges B, Rosenbauer J, Stahl-Pehe A, Flury M, Biester T, et al. 2025. Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2−20 years) with type 1 diabetes: a population-based study. The Lancet Diabetes & Endocrinology 13:88−96

doi: 10.1016/S2213-8587(24)00284-5

[48]

Maia A, Subias Andujar D, Yuste C, Albert L, Vilaverde J, et al. 2025. Time in range analysis in automated insulin delivery era: should day and nighttime targets be the same? Journal of Diabetes Science and Technology 19:1326−1330

doi: 10.1177/19322968241236456